DFNA5 Antibody (G-9): sc-393162

DFNA5 Antibody (G-9) is a mouse monoclonal IgG2a kappa light chain antibody that detects DFNA5 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). anti-DFNA5 antibody (G-9) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. DFNA5, also known as ICERE-1, consists of 496 amino acids and is primarily expressed in cochlear tissue, as well as in the placenta, brain, heart, liver, lung, and pancreas, where DFNA5 exists in two alternatively spliced isoforms, referred to as short and long. DFNA5 plays a crucial role in auditory function; mutations in the gene encoding DFNA5 are associated with non-syndromic sensorineural deafness autosomal dominant type 5, a condition that leads to hearing loss due to damage in the auditory pathways of the brain. DFNA5 is located on human chromosome 7, which contains over 1,000 genes and accounts for nearly 5% of the human genome. Notably, defects in other genes on chromosome 7 have been implicated in various genetic disorders, including Osteogenesis imperfecta and Williams-Beuren syndrome, highlighting the critical nature of this chromosomal region in human health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DFNA5 Antibody (G-9) References:

1. Is DFNA5 a susceptibility gene for age-related hearing impairment?  |  Van Laer, L., et al. 2002. Eur J Hum Genet. 10: 883-6. PMID: 12461698
2. A yeast model for the study of human DFNA5, a gene mutated in nonsyndromic hearing impairment.  |  Gregan, J., et al. 2003. Biochim Biophys Acta. 1638: 179-86. PMID: 12853124
3. The potential role of DFNA5, a hearing impairment gene, in p53-mediated cellular response to DNA damage.  |  Masuda, Y., et al. 2006. J Hum Genet. 51: 652-664. PMID: 16897187
4. A novel DFNA5 mutation does not cause hearing loss in an Iranian family.  |  Van Laer, L., et al. 2007. J Hum Genet. 52: 549-552. PMID: 17427029
5. Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma.  |  Kim, MS., et al. 2008. Oncogene. 27: 3624-34. PMID: 18223688
6. Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer.  |  Kim, MS., et al. 2008. Biochem Biophys Res Commun. 370: 38-43. PMID: 18346456
7. DFNA5, a gene involved in hearing loss and cancer: a review.  |  de Beeck, KO., et al. 2012. Ann Otol Rhinol Laryngol. 121: 197-207. PMID: 22530481
8. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death.  |  Rogers, C., et al. 2017. Nat Commun. 8: 14128. PMID: 28045099
9. DFNA5 regulates immune cells infiltration and exhaustion.  |  Hu, J., et al. 2022. Cancer Cell Int. 22: 107. PMID: 35248047
10. DFNA5 inhibits colorectal cancer proliferation by suppressing the mTORC1/2 signaling pathways via upregulation of DEPTOR.  |  Guo, J., et al. 2022. Cell Cycle. 21: 2165-2178. PMID: 35923131
11. Refined mapping of a gene for autosomal dominant progressive sensorineural hearing loss (DFNA5) to a 2-cM region, and exclusion of a candidate gene that is expressed in the cochlea.  |  Van Laer, L., et al. 1997. Eur J Hum Genet. 5: 397-405. PMID: 9450185
12. Nonsyndromic hearing impairment is associated with a mutation in DFNA5.  |  Van Laer, L., et al. 1998. Nat Genet. 20: 194-7. PMID: 9771715

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-DFNA5 Antibody (G-9) has 8 citations in a variety of scientific publications.

Primary antibodies like Anti-DFNA5 Antibody (G-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

DFNA5 Antibody (G-9) Specifications

Alternate Product Name: DFNA5

Product Clone Name: G-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 221-496

Epitope Target: DFNA5

Epitope Species: human

Product Reactivity/Detection: DFNA5

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 8 citations in various scientific publications

Available Conjugates/Forms for DFNA5 Antibody (G-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin